<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Arvinas, Inc. — News on 6ix</title>
    <link>https://6ix.com/company/arvinas-inc</link>
    <description>Latest news and press releases for Arvinas, Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 12 May 2026 11:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/arvinas-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835483c78dffbe2df0e3bc6.webp</url>
      <title>Arvinas, Inc.</title>
      <link>https://6ix.com/company/arvinas-inc</link>
    </image>
    <item>
      <title>Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-and-pfizer-enter-into-a-transaction-with-rigel-pharmaceuticals-for-the-exclusive-global-rights-of-veppanu-vepdegestrant</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-and-pfizer-enter-into-a-transaction-with-rigel-pharmaceuticals-for-the-exclusive-global-rights-of-veppanu-vepdegestrant</guid>
      <pubDate>Tue, 12 May 2026 11:00:00 GMT</pubDate>
      <description>– Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, regulatory, and commercial milestones and tiered royalites on net sales – NEW HAVEN, Conn., May 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, and Pfizer Inc. (NYSE: PFE) have entered into a license agreement with Rigel Pharmaceuticals, Inc., a commercial s</description>
    </item>
    <item>
      <title>Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-to-report-first-quarter-2026-financial-results-on-may-12-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-to-report-first-quarter-2026-financial-results-on-may-12-2026</guid>
      <pubDate>Tue, 05 May 2026 11:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that management will review first quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, May 12, 2026 at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay of the webcast will be ava</description>
    </item>
    <item>
      <title>Guardant Health Receives FDA Approval for Guardant360® CDx as a Companion Diagnostic for Arvinas and Pfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations</title>
      <link>https://6ix.com/company/arvinas-inc/news/guardant-health-receives-fda-approval-for-guardant360r-cdx-as-a-companion-diagnostic-for-arvinas-and-pfizers-veppanu-vepdegestrant-for-patients-with-erher2-advanced-breast-cancer-with-esr1-mutations-1</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/guardant-health-receives-fda-approval-for-guardant360r-cdx-as-a-companion-diagnostic-for-arvinas-and-pfizers-veppanu-vepdegestrant-for-patients-with-erher2-advanced-breast-cancer-with-esr1-mutations-1</guid>
      <pubDate>Mon, 04 May 2026 12:05:00 GMT</pubDate>
      <description>PALO ALTO, Calif., May 04, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the Guardant360® CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). VEPPANU, jointly developed by Arvinas, Inc. and Pfizer Inc., is approved for the treatment of adults with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (</description>
    </item>
    <item>
      <title>Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-announces-fda-approval-of-veppanu-vepdegestrant-for-the-treatment-of-esr1m-erher2-advanced-breast-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-announces-fda-approval-of-veppanu-vepdegestrant-for-the-treatment-of-esr1m-erher2-advanced-breast-cancer</guid>
      <pubDate>Fri, 01 May 2026 04:00:00 GMT</pubDate>
      <description>– VEPPANU™ is the first-and-only FDA-approved PROTAC, a type of heterobifunctional protein degrader – – Approval received in advance of FDA-assigned PDUFA</description>
    </item>
    <item>
      <title>Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-announces-positive-phase-1-data-for-arv-102-showing-greater-than-50percent-lrrk2-degradation-in-the-csf-of-patients-with-parkinsons-disease-treated-for-28-days</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-announces-positive-phase-1-data-for-arv-102-showing-greater-than-50percent-lrrk2-degradation-in-the-csf-of-patients-with-parkinsons-disease-treated-for-28-days</guid>
      <pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
      <description>– ARV-102 reduced endolysosomal and neuroinflammatory biomarkers implicated in Parkinson’s disease and progressive supranuclear palsy – – ARV-102 was well</description>
    </item>
    <item>
      <title>Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurological-disorders</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-to-present-phase-1-data-for-arv-102-a-protac-lrrk2-degrader-in-oral-session-at-the-2026-international-conference-on-alzheimers-and-parkinsons-diseases-and-related-neurological-disorders</guid>
      <pubDate>Wed, 11 Mar 2026 11:00:00 GMT</pubDate>
      <description>– Company to highlight new safety, pharmacokinetic, and pharmacodynamic data from Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease – NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that data from a Phase 1 clinical trial of ARV-102 in participants with Parkinson’s disease (PD) will be presented at the 2026 Interna</description>
    </item>
    <item>
      <title>Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
      <description>– Company entering 2026 with the potential to deliver multiple value-driving milestones, including data readouts from ARV-102, ARV-806, and ARV-393, with cash</description>
    </item>
    <item>
      <title>Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-report-fourth-quarter-full-120000529</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-report-fourth-quarter-full-120000529</guid>
      <pubDate>Tue, 17 Feb 2026 12:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review fourth quarter and full year 2025 financial results and provide a corporate update during a live webcast on Tuesday, February 24, 2026 at 8:00 a.m. ET. The webcast can be accessed under “Events and Presentations” on the investor page of the Arvinas website. A replay</description>
    </item>
    <item>
      <title>Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-announces-appointment-randy-teel-120000740</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-announces-appointment-randy-teel-120000740</guid>
      <pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
      <description>– Appointment of an experienced Arvinas executive with a proven ability to drive strategy and innovation positions the company for continued momentum and long-term growth – NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., as President and Chief Executive Officer (CEO), as well as a member of the Company’</description>
    </item>
    <item>
      <title>Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-presents-preclinical-data-supporting-mechanistic-synergies-and-enhanced</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-presents-preclinical-data-supporting-mechanistic-synergies-and-enhanced</guid>
      <pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
      <description>– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial to evaluate ARV-393 plus glofitamab as a chemotherapy-free combination</description>
    </item>
    <item>
      <title>Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-present-piper-sandler-37th-annual-healthcare-conference-2025-11-26</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-present-piper-sandler-37th-annual-healthcare-conference-2025-11-26</guid>
      <pubDate>Wed, 26 Nov 2025 05:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based</description>
    </item>
    <item>
      <title>Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-announces-data-presentations-vepdegestrant-arv-471-clinical-development</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-announces-data-presentations-vepdegestrant-arv-471-clinical-development</guid>
      <pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based</description>
    </item>
    <item>
      <title>Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-reports-third-quarter-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-reports-third-quarter-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Wed, 05 Nov 2025 05:00:00 GMT</pubDate>
      <description>– Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease – – Presented preclinical data</description>
    </item>
    <item>
      <title>Arvinas to Present Preclinical Data for ARV-393 at the 2025 American Society of Hematology (ASH) Annual Meeting</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-present-preclinical-data-arv-393-2025-american-society-hematology-ash-annual</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-present-preclinical-data-arv-393-2025-american-society-hematology-ash-annual</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based</description>
    </item>
    <item>
      <title>Arvinas to Participate in Upcoming Investor Conferences</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-participate-upcoming-investor-conferences-2025-11-03</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-participate-upcoming-investor-conferences-2025-11-03</guid>
      <pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based</description>
    </item>
    <item>
      <title>Arvinas to Report Third Quarter 2025 Financial Results on November 5, 2025</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-report-third-quarter-2025-financial-results-november-5-2025-2025-10-29</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-report-third-quarter-2025-financial-results-november-5-2025-2025-10-29</guid>
      <pubDate>Wed, 29 Oct 2025 04:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based</description>
    </item>
    <item>
      <title>Arvinas Presents Preclinical Data for ARV-806 Demonstrating Robust and Differentiated Activity in Models of KRAS G12D-mutated Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-presents-preclinical-data-arv-806-demonstrating-robust-and-differentiated</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-presents-preclinical-data-arv-806-demonstrating-robust-and-differentiated</guid>
      <pubDate>Fri, 24 Oct 2025 04:00:00 GMT</pubDate>
      <description>– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in models of pancreatic, colorectal,</description>
    </item>
    <item>
      <title>Arvinas to Present Preclinical Data for ARV-806, a PROTAC KRAS G12D Degrader, at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-present-preclinical-data-arv-806-protac-kras-g12d-degrader-2025-aacr-nci</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-present-preclinical-data-arv-806-protac-kras-g12d-degrader-2025-aacr-nci</guid>
      <pubDate>Wed, 22 Oct 2025 04:00:00 GMT</pubDate>
      <description>NEW HAVEN, Conn., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based</description>
    </item>
    <item>
      <title>Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy</title>
      <link>https://6ix.com/company/arvinas-inc/news/patient-reported-outcomes-veritac-2-clinical-trial-support-clinical-benefit</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/patient-reported-outcomes-veritac-2-clinical-trial-support-clinical-benefit</guid>
      <pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
      <description>– Data demonstrated that vepdegestrant maintained patients’ quality of life for statistically significantly longer and delayed worsening of overall health,</description>
    </item>
    <item>
      <title>Arvinas to Present Data from the Vepdegestrant Clinical Development Program at the 2025 European Society for Medical Oncology (ESMO) Congress</title>
      <link>https://6ix.com/company/arvinas-inc/news/arvinas-present-data-vepdegestrant-clinical-development-program-2025-european-society</link>
      <guid isPermaLink="true">https://6ix.com/company/arvinas-inc/news/arvinas-present-data-vepdegestrant-clinical-development-program-2025-european-society</guid>
      <pubDate>Mon, 13 Oct 2025 04:00:00 GMT</pubDate>
      <description>– Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial – NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE</description>
    </item>
  </channel>
</rss>